Aprea Therapeutics, Inc. (APRE) vs Enveric Biosciences, Inc. (ENVB)
A side-by-side comparison of Aprea Therapeutics, Inc. and Enveric Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ENVB
Enveric Biosciences, Inc.
$1.47HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — APRE vs ENVB
growth of $100 · dividends reinvested · last 7yAPRE -99.8% (-57.8%/yr)ENVB -100.0% (-76.8%/yr)APRE compounded faster over this window
Log scale — wide-divergence pair
APRE ENVB
APRE vs ENVB: by the numbers
- •APRE is the larger company ($8M vs $7M market cap).
Metrics side by side
Valuation
| Metric | APRE | ENVB |
|---|---|---|
| P/B ratio | 0.20 | 0.81 |
Profitability
| Metric | APRE | ENVB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -31.99% | -108.00% |
| ROIC | -33.73% | -107.99% |
Growth (annualized)
| Metric | APRE | ENVB |
|---|---|---|
| Total return CAGR (5Y) | -63.30% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.